ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Japanese government has awarded Takeda Pharmaceutical $312 million to help it invest in pandemic H5N1 flu vaccine development and manufacturing. The company is in the process of implementing in Japan a flu vaccine technology, based on Vero cells, that it licensed from Baxter International. Takeda will proceed with the construction of a commercial facility at its Hikari site, with the aim of obtaining regulatory approval for its vaccines during the 2013 fiscal year. Last year, Japan provided $47 million for the company to test Baxter’s cell-culture and purification techniques at Hikari.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter